Pandion Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Pandion Therapeutics's estimated annual revenue is currently $9.5M per year. 0
- Pandion Therapeutics's total funding is $138M.
Employee Data
- 00
Pandion Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Associate Scientist II (Immunology) | Reveal Email/Phone |
Pandion Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Pandion Therapeutics?
Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory disease and organ transplants. Our localized approach represents a significant change from the systemic immunosuppression of conventional medicines, which often have dose-limiting safety concerns and can cause serious infections and cancer. Furthermore, through tissue-specific therapeutic targeting, Pandionￃﾢ￢ﾂﾬ￢ﾄﾢs approach has the potential to more effectively induce and sustain response and remission in patients with many autoimmune and inflammatory conditions. We aim to shift the paradigm and create a new generation of drugs with transformative efficacy and improved safety.
keywords:N/A
$138M
Total Funding
N/A
Number of Employees
$9.5M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Pandion Therapeutics News
Prior to joining Seismic, Eric was Vice President of Finance at Pandion Therapeutics where he built the finance and accounting...
... Fresenius Kabi, OSE Immunotherapeutics, Enthera, Theravance, Pandion Therapeutics, Gossamer Bio, Viatris, and Thermo Fisher; grants from AbbVie, MSD,...
Ultimately, our investment in Pandion Therapeutics helped catalyze their pancreas program, which started off with a relatively small investment...
Pandion Therapeutics, Inc., a Cambridge, MA-based clinical-stage, biotechnology company developing modular protein therapeutics for autoimmune disease, closed an $80m Series B financing. The round was led by Access Biotechnology and Boxer Capital with participation from RA Capital and OrbiMed a ...
Pandion Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation, completed a $58m Series A financing. The round was co-led by Polaris Partners, Versant Ventures and Roche Venture Fund, with participatio ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $64.9M | 0 | N/A | $751.3M |
#2 | $12.9M | 0 | N/A | $163M |
#3 | $9.8M | 0 | N/A | $39M |
#4 | $4.8M | 0 | N/A | N/A |
#5 | $33.3M | 0 | N/A | $15M |